The HABP4 Knockout NCI-H1975 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population engineered from the NCI-H1975 human non-small cell lung adenocarcinoma cell line. This product features a genetically heterogeneous pool of cells with targeted disruption of the HABP4 locus, providing a powerful loss-of-function model for studying the gene’s role in cell adhesion, migration, and tumor metastasis. As a polyclonal population, it preserves the complexity of knockout events across the cell pool, making it suitable for bulk phenotypic assays without the clonal biases inherent to single-cell-derived lines. Researchers can interrogate the collective impact of HABP4 ablation on signaling networks and cellular behaviors in a relevant lung cancer background.
The parental NCI-H1975 cell line was derived from the metastatic pleural effusion of a non-smoking female patient with lung adenocarcinoma. It endogenously harbors activating EGFR L858R and resistance-conferring T790M mutations, along with a TP53 mutation, reflecting a clinically relevant EGFR-mutant non-small cell lung cancer model. These cells are widely employed to investigate EGFR tyrosine kinase inhibitor (TKI) sensitivity, resistance mechanisms, and downstream oncogenic signaling. The adherent epithelial morphology and stable growth characteristics make NCI-H1975 a robust platform for studying tumor biology and therapeutic interventions in the context of oncogene-driven lung cancer.
HABP4 encodes an mRNA-binding protein that post-transcriptionally stabilizes SERPINE1 (plasminogen activator inhibitor-1, PAI-1) mRNA, leading to increased PAI-1 protein expression. PAI-1 is a key regulator of the plasminogen activation system, inhibiting urokinase-type plasminogen activator (uPA) and thereby suppressing plasmin-mediated matrix degradation. HABP4 also interacts with hyaluronan and microtubules, linking extracellular matrix sensing to cytoskeletal dynamics. Upstream, HABP4 expression is regulated by TGF-?? and EGFR signaling pathways, which converge on SMAD2/3 and AKT/ERK cascades. Downstream, elevated PAI-1 promotes extracellular matrix accumulation and modulates cell adhesion molecules, influencing matrix metalloproteinase (MMP) activity and integrin function. Through these interactions, HABP4 integrates signals from growth factors and the extracellular microenvironment to coordinate cell motility, adhesion, and invasive potential.
In the NCI-H1975 cellular context, HABP4 knockout is expected to attenuate PAI-1-mediated stabilization of extracellular matrix components and alter the invasive properties of EGFR-mutant lung adenocarcinoma cells. The loss of HABP4 may reduce PAI-1-driven inhibition of plasmin activation, leading to enhanced matrix remodeling and altered cell-matrix adhesion dynamics. This model provides a valuable tool to dissect the interplay between oncogenic EGFR signaling, TGF-??-induced responses, and HABP4-dependent mRNA regulation. Given the role of PAI-1 in tumor angiogenesis and metastasis, the polyclonal knockout cells offer a physiologically relevant system to study how HABP4 contributes to EGFR-TKI resistance and metastatic progression.
Typical experimental applications include evaluating PAI-1 protein levels by western blotting, measuring SERPINE1 mRNA stability via RT-qPCR, and assessing migratory and invasive capacity using transwell or wound healing assays. Cellular adhesion assays under various ECM conditions can reveal alterations in integrin-mediated attachment. Drug sensitivity studies employing EGFR inhibitors (e.g., osimertinib) in the presence or absence of HABP4 knockout enable dissection of resistance mechanisms. Phospho-kinase arrays probing EGFR downstream signaling (AKT, ERK) and TGF-??/SMAD cascade activation further elucidate pathway crosstalk. The HABP4 Knockout NCI-H1975 Polyclonal Cells are a versatile resource for investigations into lung cancer metastasis, extracellular matrix remodeling, and thrombosis-related research. For further information or to discuss workflow integration, contact Ascent Research.
